Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Loxapine for schizophrenia.

M Fenton1, B Murphy, J Wood

  • 1Leeds Social Service, Leeds Crisis Centre, 3 Spring Rd, Headingley, Leeds, West Yorks, UK, LS6 1AD. brendanm@eboli.demon.co.uk

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Taking the 'HIT' (Heparin-induced thrombocytopenia) - Balancing Local Testing with Delayed Central Results.

Irish medical journal·2026
Same author

Factors affecting prolonged Emergency Department stays in the over 75s.

Irish medical journal·2026
Same author

The effect of form on equine salt intake.

Journal of equine veterinary science·2026
Same author

Acute Respiratory Infection Outbreaks in Residential Care Facilities.

Irish medical journal·2025
Same author

At-home, self-sampling of the skin microbiome: development of an unsupervised sampling approach.

Access microbiology·2025
Same author

Estimating the Age of Disease-causal HPV Infection Based on the Natural History of CIN2+ Among Females in Canada.

Open forum infectious diseases·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Loxapine demonstrates antipsychotic properties, comparable to typical antipsychotics in short-term use. However, its effects and side-effect profile require further research to fully understand its therapeutic potential in schizophrenia treatment.

Area of Science:

  • Psychiatry and Pharmacology
  • Neuroscience
  • Clinical Psychology

Background:

  • Loxapine exhibits D2/D3 receptor antagonist activity, with a higher affinity for D3 receptors.
  • Some research suggests loxapine may be more effective than typical antipsychotics for negative schizophrenia symptoms.
  • It is proposed that loxapine could be classified as an atypical antipsychotic due to a potentially favorable side-effect profile.

Purpose of the Study:

  • To evaluate the efficacy and safety of loxapine compared to placebo, typical, and atypical antipsychotic medications.
  • To determine the comparative effects of loxapine in treating schizophrenia and related psychoses.

Main Methods:

  • Comprehensive electronic database searches were conducted from 1966 to 1999.
  • Included were randomized controlled trials comparing loxapine with other treatments for schizophrenia.

Related Experiment Videos

  • Data extraction and quality assessment were performed independently, with a 50% loss to follow-up exclusion criterion.

    • Main Results:

    • Loxapine shows antipsychotic effects compared to placebo, with a Number Needed to Treat (NNT) of 4 for global improvement at 6 weeks.
    • Its adverse effect profile appears similar to typical antipsychotic drugs.
    • Short-term efficacy (4-12 weeks) is comparable to typical antipsychotics; limited data suggest intramuscular loxapine may be as sedating as haloperidol or thiothixene.

    Conclusions:

    • Loxapine is confirmed as an antipsychotic medication.
    • Current research indicates its effects are not significantly different from typical antipsychotics regarding positive or adverse effects.
    • Further investigation is needed to fully elucidate the therapeutic profile of loxapine.